In recent years, newly developed biological agents such as IL-23 inhibitors and TNF-α inhibitors seem to have brought new hope to patients with severe psoriasis, but the high treatment cost or some adverse reactions limit the widespread use of these drug (12). This evidence concerns the gene TNF and psoriasis.